Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany

Overview of attention for article published in Orphanet Journal of Rare Diseases, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 35 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

Risdiplam’s Real-World Safety Profile Mirrors That of Clinical Trials

AJMC, 09 Nov 2022

The new data suggest risdiplam can be a viable option for people with spinal muscular atrophy who cannot take or tolerate the 2…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.